Symposium and workshop – actual challenges and implementation of new technologies in the treatment of chronic myeloid leukaemia
Authors:
N. Čuřík 1,2
Authors‘ workplace:
Ústav hematologie a krevní transfuze, Oddělení molekulární genetiky, Praha 2 Ústav patologické fyziologie, 1. LF UK, Praha
1
Published in:
Transfuze Hematol. dnes,29, 2023, No. 1, p. 79-81.
Category:
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 1
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
Most read in this issue
- Recommendations of the Czech Society of Haematology for the diagnosis and treatment of immune thrombocytopenia in adults
- Recommendations for thrombotic risk stratification and targeted thromboprophylaxis in women during assisted reproduction
- Blast phase of chronic myeloid leukaemia
- Rare and unfavorable course of chronic myeloid leukemia – a case report and review of the literature